The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...
The drug will be marketed under the brand name Alyftrek. Post the FDA’s approval, the orally administered Alyftrek has been approved for use in CF patients aged six years and older who have at least ...
Truist analyst Joon Lee lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy ...
We're seeing such opportunities in the market right now. Here are three no-brainer stocks to buy during the latest sell-off.
More importantly, the FDA approved Alyftrek in treating cystic fibrosis (CF). I predict this new product will become Vertex's most successful CF therapy yet. I also expect Vertex will soon win FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback